Saline mist and chest taps: could this combo help sick babies breathe easier?
NCT ID NCT06441162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether giving infants with bronchiolitis a saltwater mist plus gentle chest tapping every 6 hours helps them get better faster. The trial included 75 babies under 2 years old who were in the hospital and needed extra oxygen. Unfortunately, the study was stopped early, so we don't have clear answers yet.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nebulized 3% hypertonic saline
- What this could lead to
- If it worked, this combination might shorten hospital stays and reduce oxygen needs for infants with bronchiolitis.
- What could go wrong
- The study was terminated early, so results are limited. It was small (75 participants) and not randomized, making it hard to draw firm conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
75 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
0 to 24 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: In order to be eligible to participate in this study (experimental arm), an individual must meet all of the following criteria: * Age 0 to 24 months * Admitted to the general inpatient pediatrics unit * Has a diagnosis of acute bronchiolitis * Receiving supplemental oxygen support Data collected for the control arm will be obtained via retrospective chart review for patients meeting the following inclusion criteria: * Age 0 to 24 months * Admitted to the general inpatient pediatrics unit * Has a diagnosis of acute bronchiolitis * Receiving supplemental oxygen support Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Admitted to the pediatric intensive care unit * Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.) * Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.) * Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction * Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol) * Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics A potential study subject in the control arm via retrospective chart review who meets any of the following criteria will be excluded from this study: * Admitted to the pediatric intensive care unit * Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.) * Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.) * Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction * Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol) * Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute bronchiolitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
Mineola, New York, 11501, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 5-Minute ultrasound could reveal how sick a Baby's lungs really are
- Could a common asthma drug shorten bronchiolitis hospital stays?
- New study aims to predict severe bronchiolitis in infants
- New study aims to curb antibiotic overuse for coughs and colds
- Could stopping oxygen therapy earlier get bronchiolitis babies home sooner?
- Heart scan may forecast ICU stay for babies with severe bronchiolitis